Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Methods Mol Biol. 2024;2789:185-192. doi: 10.1007/978-1-0716-3786-9_19.
Polyethylene glycol, or PEG, is common in consumer products, over-the-counter medications, food, and pharmaceutical products. Concerns about PEG immunogenicity and the subsequent negative impact of pre-existing and product-induced antibodies often shadow the benefits of using PEG in nanotechnology-based products. Such anti-PEG antibodies contribute to the accelerated blood clearance of PEGylated nanomedicines and result in premature drug release and antibody-mediated toxicities. Recent data demonstrated that using PEG in COVID-19 lipid nanoparticle-mRNA vaccines is associated with an induction of anti-PEG antibodies in healthy individuals, further contributing to the development or boosting of pre-existing antibodies and increasing the risks of antibody-mediated toxicities to other products containing PEG. Therefore, monitoring the levels of pre-existing and product-induced anti-PEG antibodies provides mechanistic insights for pharmacology, toxicology, and immunological studies of PEGylated drug products.
聚乙二醇（PEG）在消费品、非处方药、食品和药品中很常见。PEG 的免疫原性以及由此产生的预存抗体和产品诱导抗体的负面影响，常常使人们忽视了 PEG 在基于纳米技术的产品中的应用优势。这些抗 PEG 抗体导致 PEG 化纳米药物的血液清除加速，导致药物提前释放和抗体介导的毒性。最近的数据表明，在 COVID-19 脂质纳米颗粒-mRNA 疫苗中使用 PEG 会导致健康个体产生抗 PEG 抗体，进一步促进预存抗体的产生或增强，并增加其他含有 PEG 的产品发生抗体介导毒性的风险。因此，监测预存和产品诱导的抗 PEG 抗体水平，为 PEG 化药物产品的药理学、毒理学和免疫学研究提供了机制见解。
